ArticleCells2022
Physiactisome: A New Nanovesicle Drug Containing Heat Shock Protein 60 for Treating Muscle Wasting and Cachexia.
Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Nanotechnological Strategies to Promote Skeletal Muscle Regeneration in Aging.International journal of molecular sciences · 2026Review
- Tumor-muscle communication in cancer-associated cachexia (Review).Oncology letters · 2026Review
- Nanomedicine novel strategies: deciphering the EV-metabolic axis as a natural nanocarrier network in lung cancer progression and cachexia.Journal of nanobiotechnology · 2026Review
- Exercise rejuvenates the "muscle-heart" crosstalk: skeletal muscle-derived exosomal miRNAs in cardiac aging.Frontiers in cardiovascular medicine · 2026Review
- Physical Activity, Exerkines, and Their Role in Cancer Cachexia.International journal of molecular sciences · 2025Review
- Does Vitamin B6 Act as an Exercise Mimetic in Skeletal Muscle?International journal of molecular sciences · 2024Review
- Extracellular vesicles in cancer cachexia: deciphering pathogenic roles and exploring therapeutic horizons.Journal of translational medicine · 2024Review
- Exosomes in the pathogenesis and treatment of cancer-related cachexia.Journal of translational medicine · 2024Review
- The role of extracellular vesicles in skeletal muscle wasting.Journal of cachexia, sarcopenia and muscle · 2023Review
- Cancer-associated cachexia - understanding the tumour macroenvironment and microenvironment to improve management.Nature reviews. Clinical oncology · 2023Review
- Exosome-mediated regulatory mechanisms in skeletal muscle: a narrative review.Journal of Zhejiang University. Science. B · 2023Review
- Muscle-derived exosomes and exercise in cancer prevention.Frontiers in molecular medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, no commercially available drugs have the ability to reverse cachexia or counteract muscle wasting and the loss of lean mass. Here, we report the methodology used to develop Physiactisome-a conditioned medium released by heat shock protein 60 (Hsp60)-overexpressing C2C12 cell lines enriched with small and large extracellular vesicles. We also present evidence supporting its use in the treatment of cachexia. Briefly, we obtain a nanovesicle-based secretion by genetically modifying C2C12 cell lines with an
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.